Uji klinis Glaukoma di Texas
8 studi untuk Glaukoma mencari peserta di lokasi di Texas.
Teks studi resmi (Bahasa Inggris)
iDose TR Administration in an Office-Based Surgery Setting
- Glaukos Investigative Site, Austin
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07816692Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
- Glaukos Clinical Site, El Paso
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT07075718Clarifying the Optimal Application of SLT Therapy Trial
- Ophthalmology Associates, Fort Worth
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Agu 2026 · NCT04967989Rocklatan vs Latanoprost Post-DSLT
- Eye Centers of Southeast Texas, Beaumont
Menerima pesertaFase 4
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Mei 2026 · NCT07465913Change in IOP Fluctuation After DSLT
- Ophthalmology Associates, Fort Worth
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Apr 2026 · NCT07428668Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma
- Glaucoma Associates of Texas, Dallas
- University of Texas Southwestern, Dallas
Menerima peserta
Usia 45 ke atas · Semua jenis kelamin · Diperbarui 15 Des 2025 · NCT07220876Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
- R and R Eye Research, LLC, San Antonio
Menerima pesertaFase 3
Usia 22 ke atas · Semua jenis kelamin · Diperbarui 20 Okt 2025 · NCT07218796Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
- Houston Eye Associates, Houston
Menerima pesertaFase 3
Usia 22 ke atas · Semua jenis kelamin · Diperbarui 20 Okt 2025 · NCT07218783Dari ClinicalTrials.gov, data diambil 3 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.